Growing workload
Cancer incidence and diagnostic complexity keep rising, and every case still needs expert eyes.
AI × MedTech · Singapore
Magnify what *matters.*
A!Mag builds trusted, explainable AI infrastructure for pathology, so hospitals can detect cancer earlier and pathologists can decide with evidence they can see.
Scroll
BaseSingapore · 1.35° N, 103.82° E
Local time--:--:-- SGT
StatusEarly stage · Angel round
ApproachOpen-source core · Enterprise products
A!Mag MedTechPowered by intelligence. Driven by care.
Scroll to draw
Why we exist
Pathology is the gold standard for diagnosing cancer. Yet hospitals face rising workloads, a global shortage of pathologists, and AI tools that fail to travel between hospitals, scanners and staining protocols. A!Mag builds the infrastructure layer that lets AI earn clinical trust: robust across sites, explainable to clinicians, and validated where it will be used.
Field note
Built to see what the eye can miss.
The clinical problem
Pathology is under pressure.
Pathology is central to cancer care, but the system is under structural and technical pressure at the same time.
Shortage of experts
Experienced pathologists are scarce and unevenly distributed across regions and hospitals.
Generalisation gap
Most AI models work on the dataset they were trained on, then fail across hospitals, scanners and stains.
Black-box AI
Predictions without evidence are hard to trust, hard to regulate and hard to adopt in routine practice.
Existing AI can impress in benchmarks and still fail to deliver trusted deployment in routine clinical practice.
Showcase
01/08
One slide.
Every answer.
Follow a single glass slide through the A!Mag platform, from scanner to signed report.
Scroll to explore
The slide
Glass in, pixels out.
A stained glass slide is scanned into a gigapixel whole-slide image: the raw material of every A!Mag model.
The platform
One platform, every scanner.
Models, data pipelines and workflow tools built to generalise across hospitals, scanners, stains and patient populations.
The evidence
Explainable by design.
Every call comes with evidence a pathologist can see and check: heatmaps and regions, not a black-box score.
The data
An ecosystem of data.
Secure, multi-institutional data, so models learn from many hospitals and keep working when they travel.
The pathologist
Built beside, not instead.
The pathologist still signs the report. A!Mag magnifies what matters, so decisions are faster and better evidenced.
A!Prostate
A!Gastric
A!Breast
A!Lymphoma
A!Colon
A!LungThe A! family
One lead product, five on the roadmap.
A!Prostate leads. Gastric, breast, lymphoma, colorectal and lung follow on the same platform.
Look closer with us.
Hospitals, partners and investors: the next slide could be yours.
The platform
From slide to decision.
A full-stack AI pathology architecture, from data to clinical workflow. Each layer is built to generalise across hospitals, scanners, stains and populations.
- 01
Clinical data
Whole-slide images, metadata and expert annotations, with quality control at the source.
- 02
Foundation models
Self-supervised learning combined with supervised clinical learning and pathologists' domain knowledge.
- 03
Explainable AI
Evidence regions, similar cases and reasoning support that pathologists can inspect.
- 04
Clinical AI
Diagnostic modules, quality control and reporting support for specific diseases.
- 05
Workflow
Hospital integration, deployment and monitoring inside existing pathology operations.
Magnification
Explainable by design
See what the AI sees.
Every A!Mag prediction comes with evidence: the regions that drove it, comparable cases and a reasoning summary a pathologist can check at a glance. Switch on the evidence overlay and change magnification to explore.
- Evidence regionsHeatmap of the areas that drove the prediction.
- Similar casesReference cases with comparable morphology.
- Reasoning summaryA plain-language rationale, with the rules it followed.
- Quality controlFocus, staining and artefact checks before analysis.
Illustration of the interface concept. Not clinical output.
Inside A!Mag
Built in motion.
The people, the machine and the platform behind the work. Drag to explore.
Go deeper
Explore A!Mag.
The platform, the investment case and the questions we hear most, each on its own page.
Platform & solutions
The three pillars, the A! product family, the open ecosystem model and how the technology is validated.
Open pageFor investors
Why now, the investment highlights, the diversified revenue model and the team structure.
Open pageCommon questions
Short answers for hospitals, partners and investors.
Open pageContact
Let's talk.
Hospitals, laboratories, industry partners and investors: tell us what you are working on.
We keep our team private online. Every enquiry is read and answered personally.
Or email us directly at
Your enquiry is ready.
We copied it to your clipboard. Send it to the address below, or open your mail app.
Platform & solutions
One platform. Many clinical answers.
How A!Mag turns whole-slide images into trusted, explainable decisions, and the products, ecosystem and validation behind it.
What sets the platform apart
Built to travel between hospitals.
A full-stack AI pathology architecture, from data to clinical workflow. Each layer is built to generalise across hospitals, scanners, stains and populations.
What sets the platform apart
Quality at the source
Digital pathology image quality control, interactive visualisation and efficiency quantification, with data security and usage authorisation built in.
Generalisation and explainability
Consistent accuracy across hospitals and scanners; explainable reports with reasoning and logical analysis; multiscale diagnosis built on pathologists' prior knowledge.
Many models, one platform
Multiple validated models that answer urgent needs in pathology with reliable AI solutions.
The journey of a slide
From glass to signed report.
- 01
Clinical data
Whole-slide images, metadata and expert annotations, with quality control at the source.
- 02
Foundation models
Self-supervised learning combined with supervised clinical learning and pathologists' domain knowledge.
- 03
Explainable AI
Evidence regions, similar cases and reasoning support that pathologists can inspect.
- 04
Clinical AI
Diagnostic modules, quality control and reporting support for specific diseases.
- 05
Workflow
Hospital integration, deployment and monitoring inside existing pathology operations.
Scroll to move the slide
How it works
Explainability, shown.
An illustrative example of what the pathologist sees: the slide, the model's evidence and the reasons behind a flag. Synthetic image, not patient data.
01
The slide
A whole-slide image, viewed at 20×.
Evidence regionSimilar casesConfidence shown, never hidden
02
The evidence
The regions that drove the call, shown as a heatmap the pathologist can inspect and challenge.
Draft report
- Finding: suspicious region
- Evidence attached
- Similar cases: 3
- Awaiting pathologist sign-off
03
The report
A structured draft with the evidence attached. The pathologist decides and signs.
Illustrative · synthetic data
The platform
One platform, every scanner.
Solutions
Three pillars. One platform.
Open innovation at the core, enterprise value at scale. One architecture supports open adoption and enterprise-grade products for hospitals and industry.
A!MagCore
AI infrastructure platform
Foundation models, digital pathology data infrastructure, annotation and knowledge management, quality control, explainable AI frameworks and secure computing environments.
A!MagClinical
Disease-specific AI products
Clinical applications that fit into routine pathology workflows and are built for regulatory approval, starting with prostate cancer diagnosis and grading.
A!MagEnterprise
Services and ecosystem
Deployment, clinical validation, model customisation, regulatory support, education and hospital digital transformation, delivered with clinical and industry partners.
The A! family
Start with low-friction tools; expand into regulated diagnostic products.
Tap a card to reveal the organ
A!MagQCInfrastructure
Digital pathology quality control
- Focus98%
- Stain94%
- Artefacts6%
A!MagQCLive
A!SecureInfrastructure
Data protection and usage authorisation
- Encryption100%
- Audit log100%
- Consent91%
A!SecureLive
A!HistoCloudsInfrastructure
Visualisation and annotation platform
- Sync100%
- Sites online72%
- Viewer88%
A!HistoCloudsLive
A!ProstateFirst diagnostic model
Prostate cancer diagnosis and grading
A!Prostate
A!GastricModel under development and validation
Gastric cancer diagnosis support
A!Gastric
A!BreastModel under development and validation
Breast cancer pathology
A!Breast
A!LymphomaModel under development and validation
Lymphoma classification and grading
A!Lymphoma
A!ColonModel under development and validation
Colorectal classification and grading
A!Colon
A!LungModel under development and validation
Lung pathology
A!Lung
Products are in development and clinical evaluation. Availability depends on regulatory clearance in each market.
Ecosystem
Open to inspire. Commercial to sustain. Impact to scale.
A!Mag uses openness to build ecosystem gravity and captures value through enterprise-grade products. Core infrastructure and selected frameworks will be openly available; validated clinical applications, proprietary models and enterprise services sustain the company.
- 1Open sourceFree tools and standards
- 2CommunityResearchers and hospitals
- 3ValidationPilots and reference datasets
- 4EnterpriseDeployment and support
- 5Clinical productsRegulated modules
Working with
An ecosystem, not a vendor list.
Hospitals, research institutes and industry partners build on the platform together. Partner names are shared on enquiry.
Public hospitals
Pathology labs
Research institutes
Scanner & LIS vendors
Pharma & biotech
Investors
Clinical validation
Built with pathologists. Validated across sites.
Clinical credibility is central to A!Mag. The technology has been developed in close collaboration with hospitals, pathologists and research institutions in Singapore and China, and evaluated across sites rather than on a single dataset.
Multi-centre studies
Robustness beyond a single site.
Reader studies
Human and AI collaborative diagnosis.
Cross-scanner tests
Real-world deployment conditions.
Peer-reviewed publications
Evidence in the scientific record.
SingaporeASEAN hub
Close connections with major public hospitals and national pathology groups through a national AI digital pathology programme.
ChinaScale partner
Collaborative relationships with leading hospitals and pathology centres, enabling large-scale data access and clinical evaluation.
Ready to look closer?
Hospitals, partners and investors: tell us what you are working on and we will respond personally.
Investors
Why now, and why A!Mag.
The trends converging on pathology AI, the investment case, the revenue model and how the team is structured.
At a glance
0cancer types in the A! family
0lead clinical product: A!Prostate
0platform pillars: Core, Clinical, Enterprise
0trends converging on pathology AI
Why now
Four trends are converging.
The opportunity is to build the operating layer for AI-enabled pathology, beyond any single algorithm.
Digital pathology adoption
Hospitals are moving from glass slides to whole-slide imaging.
Foundation AI
Representation learning can unlock multi-disease pathology models.
Precision medicine
Cancer care needs richer diagnostic and biomarker interpretation.
Pathologist shortage
Rising workload demands scalable decision support.
For investors
A platform company, ahead of Series A.
A!Mag combines national-scale AI pathology assets, clinical credibility and an open ecosystem strategy into a scalable MedTech AI venture. The company is early-stage and is raising its angel round to anchor value and prepare for Series A.
Founder-led scientific depth, a professional operating lead, and an advisory board of pathologists, AI experts, regulatory advisors and commercial partners.
Request the executive deck
The deck, data room and team details are shared with qualified investors on request.
- National programme foundationTechnology and clinical translation rooted in Singapore's national AI-based digital pathology programme.
- Multi-centre clinical networkMajor Singapore hospitals and leading pathology partners in China.
- Platform, beyond one modelInfrastructure, clinical applications and enterprise services on one shared foundation.
- Capital-efficient entryAn angel round before institutional Series A, with scientific depth and a professional operating team.
Diversified revenue model
The team, kept private online
Founder & Scientific LeadAn internationally recognised researcher in computational pathology, biomedical imaging and medical AI, with a deep Singapore–China clinical research network.
Operating LeadRecruitment in progress: commercial execution, investor communication and company administration, separating scientific leadership from day-to-day execution.
Advisory BoardPathologists, AI experts, regulatory advisors and commercial and strategic partners.
Names and CVs are shared on enquiry.
Roadmap
Where the platform goes next.
Milestones, not promises: the sequence we are building toward. Dates and figures are shared with qualified investors.
Now
Open-source core
The shared platform foundation, built with hospitals.
Now
A!Prostate
Lead clinical product: prostate cancer diagnosis and grading.
Now
Angel round
Anchoring value with early investors ahead of Series A.
Next
Multi-centre validation
Validation across Singapore hospitals and partner sites in China.
Next
Series A
Institutional capital to scale the products and the ecosystem.
Then
A! family expansion
Gastric, breast, lymphoma, colorectal and lung on the same platform.
Then
Wider ecosystem
Hospitals, research and industry partners beyond Singapore.
Drag or scroll
Ready to look closer?
Hospitals, partners and investors: tell us what you are working on and we will respond personally.
Common questions
Questions we hear often.
Short answers for hospitals, partners and investors. Anything else, ask us directly.
Does A!Mag replace pathologists?
No. A!Mag is decision support. The pathologist stays responsible for the diagnosis, and every AI output comes with evidence regions, similar cases and a reasoning summary, so it can be checked rather than trusted blindly.
Will it work with our scanners and staining protocols?
Generalisation across hospitals, scanners, stains and patient populations is the central design goal of the platform, and it is tested through multi-centre and cross-scanner studies rather than on a single dataset.
Is A!Mag approved as a medical device?
Not yet. Products are in development and clinical evaluation, and are designed from the start to support regulatory submissions. Availability depends on clearance in each market.
What is open source, and what is paid?
Core infrastructure components and selected development frameworks will be openly available. Validated clinical applications, proprietary models, enterprise deployment, support and regulatory-grade services are commercial.
How is patient data protected?
Data security and usage authorisation are built into the platform through A!Secure, and deployment is designed to fit the hospital’s own environment and governance requirements.
How can hospitals or investors get involved?
Hospitals and laboratories can join as validation or deployment partners; industry and pharma can partner on research and clinical trials; investors can request the executive deck. Use the enquiry form and we will respond personally.
Ready to look closer?
Hospitals, partners and investors: tell us what you are working on and we will respond personally.